Leukapheresis is a procedure used to treat chronic lymphocytic leukemia (CLL) or patients with very high white blood cell counts. During leukapheresis, patient’s blood is passed through a machine that takes out the white blood cells and returns all the other blood cells and plasma back into the bloodstream.
There is increase in number of inpatients in hospital suffering from cancer. Approach towards adoption of various treatments such as chemotherapy in order to cure the ongoing cancer is majorly preferred. According to Department of Health and Human Services, in 2018, there were an estimated 459,058 people living with leukemia in the United States. In 2021, 21,250 people of all ages (13,040 men and boys and 8,210 women and girls) in the United States will be diagnosed with CLL. While it can occur at any age, CLL is more common in older adults. The average age at diagnosis is around 70. Rising health concern among cancer patients, availability of advanced treatment, and increasing R&D activates for development of enhanced therapies are major factors expected to drive the growth of global leukapheresis market. High investment by major players for development of new solution and focus towards enhancing the business through strategic merger these factors are expected to augment the growth of target market.
In 2020, AllCells LLC, a medical service provider company enhanced the product portfolio by launching “cryopreserved leukopaks”. The product launch is focused to ensure access to high-quality primary cells without potential delivery delays. This is expected to help the company to enhance the business and increase the revenue share.
In 2020, GVS, S.p.A, a global manufacturer of filters and components for applications in the healthcare signed a strategic agreement to acquire Haemonetics Corporation company’s Fajardo, Puerto Rico manufacturing operations of blood filter facility. This acquisition is expected to help the company to enhance the business and increase the customer base.
In 2020, StemExpress, LLC, a medical service provider launched frozen leukopaks, LE00 (2.5C, 5C, 10C) addition to its present product portfolio. The frozen leukopaks, LE00 (2.5C, 5C, 10C) are frozen after fresh blood collection and provide an enriched source of peripheral blood mononuclear cells for medical research.
Availability of favorable business policies and major players approach towards tracking the untapped market in developing countries are factors expected to boost the growth of leukapheresis market. Factors such as high cost of therapeutic leukapheresis and leukopaks and stringent government regulations related to product and donors are expected to hamper the growth of global leukapheresis market. In addition lack of funding for R&D activities is expected to challenge the growth of target market. However, increasing investment by major players, rise in public-private partnership for R&D activities and introduction of innovative solutions are factors expected to create new opportunities for players operating in the leukapheresis market over the forecast period. In addition, rise in strategic partnership & agreements between regional and international player is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global leukapheresis market due to high patient pool suffering from leukemia. According to Department of Health and Human Services, the rate of new cases of leukemia was 14.3 per 100,000 men and women per year. The death rate was 6.3 per 100,000 men and women per year. Presence of large number of players operating in the country and introduction of new products in order to attract new customers is expected to impact the growth of regional market.
The market in Asia Pacific is expected to witness faster growth in the target market due to low awareness among consumers. In addition, increasing presence of favorable insurance companies and rise in screening for leukemia are factors expected to impact the leukapheresis market growth.
The global leukapheresis market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Leukapheresis Market Segment Analysis, 2019
The global leukapheresis market is segmented into type, application, and end use. The type segment is divided into leukapheresis devices and leukapheresis disposables. Among type the leukapheresis disposables segment is expected to account for major revenue share in the global leukapheresis market. The end use segment is bifurcated into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies, and hospitals and transfusion centers. The players profiled in the report are Asahi Kasei Medical Co., Ltd, Macopharma SA, Fresenius Se & Co. KGaA, Bioivt, Haemonetics Corporation, PPA Research Group, Inc., Hemacare Corporation, Key Biologics, LLC, Terumo BCT, ALLCells, LLC, and Stemexpress, LLC.
Market By Type
Market By Application
Market By End use
Blood Component Providers and Blood Centers
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Hospitals and Transfusion Centers
Rising health concern among cancer patients, availability of advanced treatment, and increasing R&D activates for development of enhanced therapies are major factors expected to drive the growth of global leukapheresis market.
In type the leukapheresis disposables segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Macopharma SA, Fresenius Se & Co. KGaA, Bioivt, Haemonetics Corporation, and PPA Research Group
The North America is expected to account for major revenue share in the global market.
In end use the hospitals and transfusion centers segment is growing at faster pace.
Factors such as high cost of therapeutic leukapheresis and leukopaks and stringent government regulations related to product and donors are expected to hamper the growth of global leukapheresis market.